Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14101 - 14125 of 14183 in total
Thiodigalactoside is a solid. This compound belongs to the dihexoses. These are disaccharides containing two hexose carbohydrates. This medication is known to target galectin-1, heat-labile enterotoxin b chain, neurocan core protein, and lactose permease.
Experimental
Matched Iupac: … (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl …
Matched Description: … This medication is known to target galectin-1, heat-labile enterotoxin b chain, neurocan core protein ... Thiodigalactoside is a solid. This compound belongs to the dihexoses. …
PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
Matched Iupac: … N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-({2-methylthieno[3,2-d]pyrimidin-4-yl}amino)- …
Matched Salts cas: … 1279034-84-2
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Radafaxine has been used in trials studying the treatment of Depressive Disorder, Major.
Investigational
Matched Iupac: … (2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol …
Investigational
Matched Iupac: … -1-yl)-N-{[4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl]methyl}acetamide ... N-[2-(diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]sulfanyl}-4-oxo-1H,4H,5H,6H,7H-cyclopenta[d]pyrimidin …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).
Investigational
Matched Iupac: … N-{5-[2-amino-7-(1-hydroxy-2-methylpropan-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]pyridin-3-yl}- ... 2-(5-chloropyridin-2-yl)acetamide …
Matched Description: … and Aged 56-75 Years (Group 2)). ... Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration ... of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein. It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the USH2A gene.
Investigational
Matched Description: … QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading …
DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.
Investigational
Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the hydrazine chemical class. It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.
Withdrawn
Matched Iupac: … (1-phenoxypropan-2-yl)hydrazine …
Matched Description: … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging …
Investigational
Matched Iupac: … 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
Experimental
Matched Iupac: … 10-[3-(dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile …
Matched Description: … Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine …
Matched Categories: … Heterocyclic Compounds, 3-Ring …
Devafidugene civaparvovec is an investigational in vivo genome editing product. It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase (IDUA) enzyme. Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
Experimental
Matched Description: … It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase …
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Serratiopeptidase is under investigation in clinical trial NCT02493179 (Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery).
Investigational
Matched Description: … Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular …
INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells.[A214475, A214478] Follow up studies in both...
Investigational
Matched Description: … [L14372] A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced ... [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. ... INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development …
Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
Investigational
Matched Description: … Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. …
Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve.
Investigational
Matched Description: … that PGE-1 alone could not achieve. ... Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet ... The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways …
Epetraborole has been used in trials studying the treatment of Infections, Bacterial, Infections, Intestinal, Infections, Urinary Tract, and Community-acquired Infection.
Investigational
Matched Iupac: … (3S)-3-(aminomethyl)-7-(3-hydroxypropoxy)-1,3-dihydro-2,1-benzoxaborol-1-ol …
Matched Salts cas: … 1234563-16-6 …
Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.
Investigational
Matched Iupac: … [(1S,2S,4R)-4-(4-{[(1S)-2,3-dihydro-1H-inden-1-yl]amino}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational
Matched Iupac: … 4-chloro-3-[5-methyl-3-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2,4-benzotriazin-7-yl]phenyl benzoate …
Matched Description: … TG100801 is a topically applied kinase inhibitor in macular degeneration patients. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Investigational
Matched Iupac: … -11-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol ... (2R)-1-{4-[(2R,4S,11R)-3,3-difluorotetracyclo[10.4.0.0^{2,4}.0^{5,10}]hexadeca-1(16),5,7,9,12,14-hexaen …
Matched Description: … It is now in "Phase 3" of clinical tests in the United States. ... Zosuquidar is a compound of antineoplastic drug candidates currently under development. …
Matched Salts cas: … 167465-36-3
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in...
Investigational
Matched Iupac: … N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide …
Matched Description: … Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Investigational
Matched Iupac: … -3-yl}-N,N-dimethyl-2-oxoacetamide ... 2-{6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methyl-1H-indol …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Investigational
Matched Iupac: … N-[2-({4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}carbamoyl)-4,5-dimethoxyphenyl ... ]quinoline-3-carboxamide …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Investigational
Matched Iupac: … 3,5-dichloro-2-methoxy-6-(trichloromethyl)-1,4-dihydropyridin-4-one …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.
Investigational
Matched Description: … ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain …
Displaying drugs 14101 - 14125 of 14183 in total